Unknown

Dataset Information

0

Elevated Endogenous SDHA Drives Pathological Metabolism in Highly Metastatic Uveal Melanoma.


ABSTRACT:

Purpose

Metastatic uveal melanoma (UM) has a very poor prognosis and no effective therapy. Despite remarkable advances in treatment of cutaneous melanoma, UM remains recalcitrant to chemotherapy, small-molecule kinase inhibitors, and immune-based therapy.

Methods

We assessed two sets of oxidative phosphorylation (OxPhos) genes within 9858 tumors across 31 cancer types. An OxPhos inhibitor was used to characterize differential metabolic programming of highly metastatic monosomy 3 (M3) UM. Seahorse analysis and global metabolomics profiling were done to identify metabolic vulnerabilities. Analyses of UM TCGA data set were performed to determine expressions of key OxPhos effectors in M3 and non-M3 UM. We used targeted knockdown of succinate dehydrogenase A (SDHA) to determine the role of SDHA in M3 UM in conferring resistance to OxPhos inhibition.

Results

We identified UM to have among the highest median OxPhos levels and showed that M3 UM exhibits a distinct metabolic profile. M3 UM shows markedly low succinate levels and has highly increased levels of SDHA, the enzyme that couples the tricarboxylic acid cycle with OxPhos by oxidizing (lowering) succinate. We showed that SDHA-high M3 UM have elevated expression of key OxPhos molecules, exhibit abundant mitochondrial reserve respiratory capacity, and are resistant to OxPhos antagonism, which can be reversed by SDHA knockdown.

Conclusions

Our study has identified a critical metabolic program within poor prognostic M3 UM. In addition to the heightened mitochondrial functional capacity due to elevated SDHA, M3 UM SDHA-high mediate resistance to therapy that is reversible with targeted treatment.

SUBMITTER: Chattopadhyay C 

PROVIDER: S-EPMC6785781 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Elevated Endogenous SDHA Drives Pathological Metabolism in Highly Metastatic Uveal Melanoma.

Chattopadhyay Chandrani C   Oba Junna J   Roszik Jason J   Marszalek Joseph R JR   Chen Ken K   Qi Yuan Y   Eterovic Karina K   Robertson A Gordon AG   Burks Jared K JK   McCannel Tara A TA   Grimm Elizabeth A EA   Woodman Scott E SE  

Investigative ophthalmology & visual science 20191001 13


<h4>Purpose</h4>Metastatic uveal melanoma (UM) has a very poor prognosis and no effective therapy. Despite remarkable advances in treatment of cutaneous melanoma, UM remains recalcitrant to chemotherapy, small-molecule kinase inhibitors, and immune-based therapy.<h4>Methods</h4>We assessed two sets of oxidative phosphorylation (OxPhos) genes within 9858 tumors across 31 cancer types. An OxPhos inhibitor was used to characterize differential metabolic programming of highly metastatic monosomy 3 (  ...[more]

Similar Datasets

| S-EPMC9090245 | biostudies-literature
| S-EPMC4490069 | biostudies-literature
| S-EPMC7565536 | biostudies-literature
| S-EPMC6632071 | biostudies-literature
| S-EPMC8368296 | biostudies-literature
| S-EPMC3935729 | biostudies-literature
| S-EPMC8280448 | biostudies-literature
| S-EPMC7871510 | biostudies-literature
| S-EPMC7772871 | biostudies-literature
| S-EPMC10147608 | biostudies-literature